Article Text

Download PDFPDF
Clinical round-up
  1. Mitesh Desai
  1. Correspondence to Mitesh Desai, Specialty Registrar in GUM, Lawson Unit, Royal Sussex County Hospital, Brighton BN2 5BE, UK;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Additional boceprevir increases sustained virological response (SVR) rates in treatment-naïve and treatment-experienced chronic hepatitis C virus (HCV) genotype 1 infection

The findings of two phase 3, double-blind, placebo-controlled trials on the additional use of HCV serine protease inhibitor, boceprevir, with the current standard of therapy–pegylated interferon α-2b (peg-IFN) and weight-adjusted ribavirin (RBV)–have recently been published.

The treatment-naïve study1 stratified patients according to black and non-black ethnicity—based on known reduced SVR rates in black patients—and comprised three treatment arms, in all of which patients received a 4-week lead-in regimen of peg-IFN+RBV and subsequently received:

  • Group 1 (controls): peg-IFN+RBV+placebo (44 weeks) (n=311 non-black)

  • Group 2: peg-IFN+RBV+boceprevir (24 weeks) plus a further 20 weeks of peg-IFN+RBV if viral load was detectable between weeks 8 and 24 (n=316 non-black)

  • Group 3: peg-IFN+RBV+boceprevir (44 weeks) (n=213 non-black)

The respective SVR rates were significantly different between the control compared with the two treatment groups: 40% (controls), 67% (group 2, p<0.001) and 68% *group 3, p<0.001). While, the numbers …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.